On December 15, 2020 Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) reported that on December 14, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting on April 24, 2015 (the "Share Option Scheme") (Press release, Hutchison China MediTech, DEC 15, 2020, https://www.chi-med.com/grant-of-share-options-under-share-option-scheme-201215/ [SID1234572854]). The scheme limit of the Share Option Scheme was refreshed on April 27, 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Chi-Med granted share options under its Share Option Scheme to employees to subscribe for a total of 1,535,580 Ordinary Shares represented by 307,116 American Depositary Shares ("ADSs") (each equating to five Ordinary Shares) subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:
Date of grant : December 14, 2020
Exercise price of share options granted : US$29 per ADS
Number of share options granted : 1,535,580 represented by 307,116 ADSs (five share options shall entitle the holder thereof to subscribe for one ADS)
Closing market price of ADSs on the date of grant : US$29 per ADS
Validity period of the share options : From December 14, 2020 to December 13, 2030
Among the share options granted, a total of 58,570 share options represented by 11,714 ADSs were granted to Mr Christian Hogg and Dr Weiguo Su (Executive Directors of the Company), being persons discharging managerial responsibility under the EU Market Abuse Regulation as follows:-
Grantee Number of share options granted
Mr Christian Hogg (Executive Director and Chief Executive Officer) 39,610 Ordinary Shares represented by 7,922 ADSs
Dr Weiguo Su (Executive Vice President and Chief Scientific Officer) 18,960 Ordinary Shares represented by 3,792 ADSs
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Mr Christian Hogg
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Christian Hogg
2 Reason for the notification
a) Position/status Executive Director and Chief Executive Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hutchison China MediTech Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Option over American Depositary Share (each equating to five Ordinary Shares of US$0.10)
Option over American Depositary Share with ADS ISIN: US44842L1035
b) Nature of the transaction
Grant of options in respect of 39,610 Ordinary Shares represented by 7,922 ADSs under the Share Option Scheme.
The share options granted are exercisable subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the effective date of grant.
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 7,922
d) Aggregated information
— Aggregated volume
— Price N/A
e) Date of the transaction 2020-12-14
f) Place of the transaction Outside a trading venue
(b) Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
2 Reason for the notification
a) Position/status Executive Director and Chief Scientific Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hutchison China MediTech Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Option over American Depositary Share (each equating to five Ordinary Shares of US$0.10)
Option over American Depositary Share with ADS ISIN: US44842L1035
b) Nature of the transaction
Grant of options in respect of 18,960 Ordinary Shares represented by 3,792 ADSs under the Share Option Scheme.
The share options granted are exercisable subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the effective date of grant.
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 3,792
d) Aggregated information
— Aggregated volume
— Price N/A
e) Date of the transaction 2020-12-14
f) Place of the transaction Outside a trading venue